Join the 'Glimepiride/Pioglitazone' group to help and get support from people like you. How it works
Glimepiride/Pioglitazone Blog
| Tweet |
Four Common Meds Send Thousands of Seniors to Hospital: CDC
Posted 23 Nov 2011 by Drugs.com
WEDNESDAY, Nov. 23 – An estimated 100,000 older Americans are hospitalized for adverse drug reactions yearly, and most of those emergencies stem from four common medications, a new study finds. The four types of medication – two for diabetes and two blood-thinning agents – account for two-thirds of those drug-related emergency hospitalizations. "Of the thousands of medications available to older patients, a small group of blood thinners and diabetes medications caused a high proportion of emergency hospitalizations for adverse drug events among elderly Americans," said lead study author Dr. Daniel Budnitz, director of the U.S. Centers for Disease Control and Prevention's medication safety program. Medications previously designated "high-risk" were implicated in only 1.2 percent of hospitalizations, the study found. Working with a nationally representative database, CDC researchers ... Read more
Related support groups: Metformin, Aspirin, Coumadin, Plavix, Warfarin, Insulin, Lantus, Januvia, Glucophage, Actos, Glyburide, Glipizide, Humalog, Janumet, Novolog
Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA
Posted 16 Jun 2011 by Drugs.com
THURSDAY, June 16 – The U.S. Food and Drug Administration is warning consumers that the popular diabetes drug Actos (pioglitazone) may increase the risk of bladder cancer when used for more than a year. The agency's warning comes five days after Germany and France pulled Actos from the market, citing similar concerns. Actos is in a class of drugs called thiazolidinediones, the only other member of which, Avandia (rosiglitazone), was taken off U.S. pharmacy shelves in May because it was linked to an increased risk of heart attacks. The new cancer warning will appear on the labeling, the FDA said. However, although Actos does have some side effects, "the beneficial effects of Actos, I think, outweigh any possible risk of cancer," said Dr. Joseph Giangola, medical director of diabetes at Hackensack University Medical Center in Hackensack, N.J. Actos is used to control blood sugar and is ... Read more
Related support groups: Actos, Pioglitazone, ActoPlus Met, Metformin/Pioglitazone, ActosPlus Met, Glimepiride/Pioglitazone, Duetact
FDA Medwatch Alert: Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer
Posted 15 Jun 2011 by Drugs.com
[UPDATED 06/15/2011] Use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer. This safety information is based on FDA's review of data from a five-year interim analysis of an ongoing, ten-year epidemiological study. The five-year results showed that although there was no overall increased risk of bladder cancer with pioglitazone use, an increased risk of bladder cancer was noted among patients with the longest exposure to pioglitazone, and in those exposed to the highest cumulative dose of pioglitazone. FDA is also aware of a recent epidemiological study ... Read more
Related support groups: Actos, Pioglitazone, ActoPlus Met, Metformin/Pioglitazone, ActosPlus Met, Glimepiride/Pioglitazone, Duetact
Diabetes Drugs Might Lower Risk of Lung Cancer
Posted 3 Nov 2010 by Drugs.com
TUESDAY, Nov. 2 – Researchers report that drugs used to treat diabetes may indeed both prevent and contain lung cancer. The findings, being presented Tuesday at the annual meeting of the American College of Chest Physicians in Vancouver, back up preliminary data that some diabetes medications might protect against tobacco-induced lung cancer. "Patients who did not develop lung cancer had a much higher chance of taking one of these medications than those who did develop lung cancer," said study author Dr. Peter Mazzone. "And those who did develop lung cancer were much less likely to have seen that cancer spread outside the chest and more likely to survive longer with one of these drugs." Both metformin and the class of drugs known as thiazolidinediones (which includes Avandia and Actos) are used by tens of millions of Americans. A mouse study published in September found that metformin ... Read more
Related support groups: Metformin, Glucophage, Actos, Janumet, Lung Cancer, Avandia, Glucophage XR, Pioglitazone, ActoPlus Met, Avandamet, Glumetza, Fortamet, Metformin/Pioglitazone, Riomet, Glucovance
FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure
Posted 20 Sep 2010 by Drugs.com
Safety Announcement Additional Information for Patients Additional Information for Healthcare Professionals Data Summary References Safety Announcement [09-17-2010] The U.S. Food and Drug Administration (FDA) is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone), is associated with an increased risk of bladder cancer. Findings from studies in animals and humans suggest this is a potential safety risk that needs further study. Actos is used along with diet and exercise to control blood sugar or improve control of blood sugar in adults with type 2 diabetes mellitus. Bladder cancer is estimated to occur in 20 per 100,000 persons per year in the United States and is thought to be higher in diabetics.1 The drug manufacturer, Takeda, has conducted a planned analysis of the study data at the five-year mark, and submitted their r ... Read more
Related support groups: Actos, Pioglitazone, ActoPlus Met, Metformin/Pioglitazone, ActosPlus Met, Glimepiride/Pioglitazone, Duetact
Diabetes Drugs Go Head-to-Head in Study
Posted 4 Dec 2009 by Drugs.com
THURSDAY, Dec. 3 – A class of drugs still taken by millions of people with type 2 diabetes is associated with a higher risk of dying and heart failure than the newer treatment metformin, researchers say. Sulfonylureas, long a mainstay of diabetes treatment, performed less well than metformin in a study of oral anti-diabetes drugs, but doctors said the findings aren't necessarily a reason to discontinue taking them. Glyburide, glipizide and glimepiride are examples of sulfonylureas. Metformin, which is sold as Glucophage and other brand names, is already the first-choice therapy for type 2 diabetes, and the findings are in line with new American Diabetes Association recommendations, meaning the results won't change the way patients are already treated. "This raises some interesting points for other, more specific research, but it won't affect the way we practice medicine tomorrow," said ... Read more
Related support groups: Diabetes, Type 2, Metformin, Glucophage, Actos, Glyburide, Glipizide, Janumet, Amaryl, Avandia, Glimepiride, Pioglitazone, Glucophage XR, GlipiZIDE XL, ActoPlus Met, Glucotrol